查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086946

次世代定序：市場洞察、競爭格局與市場預測（2034 年）

Next Generation Sequencing - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

次世代定序市場概述

概述：

  • 預計到 2025 年，次世代定序市場規模將達到 132.4 億美元，到 2034 年將達到 426.8 億美元。這一成長是由定序成本的快速下降、全球癌症和遺傳疾病負擔的加重以及綜合基因組分析成為保險覆蓋的常規臨床實踐所推動的。
  • 全球次世代定序市場預計在 2026 年至 2034 年的預測期內將以 13.9% 的複合年成長率成長。
  • 以產品細分市場來看，預計到 2025 年，耗材細分市場將佔市場佔有率的 51%，進而推動次世代定序市場的發展。
  • 按技術分類，「合成定序(SBS)」細分市場預計到 2025 年將佔 62% 的市場佔有率，引領次世代定序市場。
  • 按應用領域分類，預計腫瘤學領域將引領次世代定序市場，到 2025 年將佔據 41% 的市場佔有率。
  • 按最終用戶分類，預計到 2025 年，學術和研究機構將佔市場佔有率的 36%，引領次世代定序市場。
  • 預計到 2025 年，北美將佔據 42% 的市場佔有率，推動次世代定序市場的全球銷售，並成為全球市場佔有率最高的地區。

次世代定序（NGS），也稱為高通量定序或大規模定序，是指一系列能夠並行讀取數百萬個DNA或RNA片段的技術，可在數小時內而非數年內產生全基因組、全EXOME或標靶定序資料。此類別包括基於合成定序和半導體定序的短讀長平台，以及長讀長單分子定序和奈米孔系統，所有定序都依賴包含樣品製備耗材、儀器、生物資訊軟體和外包定序服務的工作流程。在過去的十年中，NGS已從一種研究工具發展成為一種臨床基礎設施，廣泛應用於腫瘤學、生殖醫學、罕見疾病診斷、感染疾病監測和藥物基因體學等領域。

次世代定序市場的主要市場促進因素

  • 人類基因定序的成本已從 2001 年的約 9,500 萬美元大幅下降到 2022 年的 5.25 億美元，預計到 2023 年，在高通量定序中心，成本還將進一步下降到約 2 億美元，使其更加經濟實惠，也更容易獲得。
  • 全球癌症負擔日益加重，推動了對基於 NGS 的診斷的需求，2022 年報告了 2000 萬例新增癌症病例，預計到 2050 年將達到 3500 萬例。
  • NGS在腫瘤分析、精準腫瘤學和伴隨診斷領域的應用日益廣泛，推動了市場成長。
  • 隨著NGS技術在生殖健康篩檢、罕見疾病診斷和感染疾病監測等領域的臨床應用不斷擴展，其使用也日益增加。
  • 技術進步，例如長讀定序平台和人工智慧驅動的生物資訊解決方案的開發，正在提高定序的準確性、效率和數據解釋能力。
  • 政府和公共部門透過國家基因組舉措和精準醫療計畫持續投資基因組研究，正在加速基因組技術的市場推廣。
  • 定序成本下降、臨床應用擴大、技術創新和資金支持等因素預計將推動全球 NGS 市場在 2034 年前保持強勁的兩位數成長。

推動次世代定序市場成長的因素

市場促進因素

定序成本的快速下降正在推動其廣泛應用。

人類基因定序的成本已從2001年的約9,500萬美元大幅下降至2022年的5.25億美元，領先的高通量定序中心在2023年實現了「200美元基因組」的目標。成本的顯著降低使NGS從以研究為中心的技術轉變為一種經濟高效的臨床和公共衛生工具，從而在腫瘤學、罕見疾病診斷、生殖醫學和大規模篩檢計畫中得到更廣泛的應用。

全球癌症負擔日益加重，加速了基因組分析的需求。

癌症發生率的不斷上升一直是推動新一代定序（NGS）技術應用的主要動力。根據國際癌症研究機構（IARC）統計，2022年全球新增癌症病例約2,000萬例，預計2050年將達到3,500萬例。隨著精準腫瘤學和標靶治療逐漸成為標準療法，全面的基因組分析和伴隨診斷對於治療方案的選擇變得日益重要，從而推動了對基於NGS的檢測及其相關耗材的需求。

市場限制因素

儘管發展勢頭強勁，但次世代定序(NGS) 市場仍面臨諸多限制因素。基於 NGS 的體外診斷 (IVD) 仍然非常複雜，因為需要適應不斷變化的美國食品藥物管理局(FDA)、歐洲體外診斷醫療器材法規 (IVDR) 以及各國臨床實驗室框架，這延長了新檢測方法的上市時間。設備購買成本高昂，耗材支出佔比也高，這意味著每個基因組的實際成本高於公佈的數據，限制了小規模檢查室採用該技術。此外，生產和供應鏈的限制，包括對少數試劑和流動池供應商的依賴，也使檢查室面臨供應風險。保險覆蓋範圍因地區和適應症而異，腫瘤學和產前檢測領域已實現全面覆蓋，但在更廣泛的應用領域則缺乏統一標準。最後，熟練的生物資訊學家短缺，以及數據存儲、解釋和臨床報告的負擔（有時被稱為“1000 美元基因組”背後的“100000 美元分析”），限制了處理能力，並延緩了資源受限環境中的採用。

競爭格局

  • 市場集中度：市場整合程度日益加劇，平台收入集中在少數幾家主要企業手中。此外，專有技術和對現有基本客群的鎖定也構成了很高的進入障礙。
  • 領導企業包括 Illumina、Thermo Fisher Scientific、Roche、QIAGEN、Pacific Biosciences 和 Oxford Nanopore Technologies，它們構成了頂尖水平。
  • 地理擴張：領先企業擁有全球銷售和支援網路，並正在推行以非洲、東南亞和拉丁美洲為目標的業務擴張計劃。
  • 產品系列優勢：領先公司提供涵蓋儀器、耗材、樣品製備和生物資訊學的一體化產品組合。
  • 研發管線優勢：我們在以下領域擁有活躍的研發管線：提高長讀長定序的準確性、提高通量、新的化學技術（如擴增定定序(SBE)）以及用於臨床的體外診斷 (IVD) 檢測。
  • 策略合作夥伴關係：我們正在透過與診斷公司、雲端和 GPU 提供者以及公共衛生組織的合作，擴大我們的業務範圍和能力。
  • 併購活動：伴隨診斷、生物資訊學和液態生物檢體相關資產的產業重組正在進行中。
  • 生產能力：大規模生產流動池和試劑的能力既是重要的競爭優勢，也是供應鏈風險。
  • 創新重點領域：努力將基因組分析成本降低到 200 美元以下，對長讀長進行臨床檢驗，以及利用人工智慧進行結果解讀。

次世代定序市場報告要點

  • 對次世代定序市場目前規模（2025 年）和 9 年市場預測（2026 年至 2034 年）進行分析。
  • 過去三年發生的重大產品和技術開發、合併、收購、合作和合資企業。
  • 引領全球次世代定序市場的領導公司。
  • 次世代定序市場為競爭者提供了各種機會。
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年將呈現哪些趨勢？
  • 目前哪些地區和國家在次世代定序市場表現最佳？
  • 企業應該將精力集中在哪些地區或國家，才能抓住次世代定序市場的成長機會？

本次世代定序市場報告的主要讀者。

  • 次世代定序產品提供商
  • 研究機構和顧問公司
  • 與次世代定序。
  • 政府機構和公司
  • 新創公司、創業投資、私募股權公司
  • 銷售代理商和公司負責次世代定序
  • 這個市場面向各種終端用戶，他們希望了解更多關於次世代定序市場及其最新技術趨勢的資訊。

常問問題：

Q1.次世代定序市場的成長率是多少？

預計從 2026 年到 2034 年的預測期內，次世代定序市場將以 13.9% 的複合年成長率成長。

Q2.次世代定序市場的市場規模有多大？

預計到 2025 年，次世代定序市場價值將達到 132.4 億美元，到 2034 年將達到 426.8 億美元。

Q3. 哪個地區在次世代定序市場中處於主導？

北美地區擁有密集的定序設備製造商和臨床實驗室，FDA對基於NGS的診斷產品核准流程完善，保險報銷政策優厚（包括CMS對全面基因組分析的報銷），以及聯邦政府對基因組研究的持續資助，預計將主導次世代定序市場，到2025年將佔全球銷售額的42%。亞太地區預計將成為預測期內成長最快的地區。

第四季：次世代定序市場的主要促進因素是什麼？

主要的驅動力是定序成本的快速下降。根據美國國家人類基因組研究所（NHGRI）的數據顯示，人類基因組定序的成本已從2001年的9,500萬美元降至2022年的525美元，預計到2023年將進一步降至200美元左右。國際癌症研究機構（IARC）預測，全球癌症新病例數將從2022年的2,000萬例增加到2050年的3,500萬例。此外，長讀長定定序和人工智慧驅動的生物資訊技術的成熟，以及臨床保險覆蓋範圍的擴大，也為定序成本的下降提供了推動作用。

Q5.次世代定序市場的主要參與者有哪些？

主要公司包括 Illumina、Thermo Fisher Scientific、F. Hoffmann-La Roche、QIAGEN NV、Pacific Biosciences of California, Inc.、Oxford Nanopore Technologies plc、BGI Genomics Co., Ltd.、Agilent Technologies, Inc.、Bio-Rad Laboratories, Inc. 和 Revvity, Inc.。其他活躍的製造商和服務供應商也包括在內，如“競爭格局”部分所述。

目錄

第1章：次世代定序市場報告簡介

  • 調查範圍
  • 市場區隔
  • 市場假設

第2章：次世代定序市場執行摘要

  • 市場概覽

第3章：次世代定序市場關鍵因素分析

  • 次世代定序市場：市場促進因素
    • 定序成本的結構性下降
    • 癌症和遺傳疾病的全球負擔日益加重
    • 長讀長定定序與人工智慧生物資訊學的成熟
    • 擴大臨床領域的保險覆蓋範圍，並增加基因組研究的公共資金投入。
  • 次世代定序市場的市場限制與挑戰
    • 監管複雜性及向體外診斷醫療器材法規 (IVDR) 的過渡
    • 高昂的資本投資成本和消耗品成本
    • 生物資訊學、資料儲存和熟練人員方面的限制
  • 次世代定序市場：市場機遇
    • 液態生物檢體和微量殘存疾病監測
    • 新興市場擴張與集體基因組學

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：次世代定序市場波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章：次世代定序市場評估

  • 按規定表格
    • 消耗品
    • 設備和平台
    • 服務
  • 透過技術
    • 合成定定序
    • 離子半導體定序
    • 單分子即時定序
    • 奈米孔定序
    • 其他
  • 透過使用
    • 腫瘤學
    • 生殖健康
    • 臨床研究與診斷
    • 藥物發現與個人化醫療
    • 農業基因組學與法醫學
    • 消費者基因體學
  • 最終用戶
    • 學術研究機構
    • 醫院和診所
    • 製藥和生物技術公司
    • 臨床和診斷檢查室
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：次世代定序市場的競爭格局

  • 市場集中度與結構

第9章：次世代定序市場的新創企業資金籌措與投資趨勢

第10章：次世代定序市場：公司概況與產品概述

  • Illumina, Inc.
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 產品系列
    • 策略舉措/熵
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies plc
  • BGI Genomics Co., Ltd.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Revvity, Inc.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0475

Next Generation Sequencing Market Summary

Overview:

  • The Next Generation Sequencing market is estimated at USD 13.24 billion in 2025 and is projected to reach USD 42.68 billion by 2034. Growth is anchored in the collapsing cost of sequencing, the rising global burden of cancer and inherited disorders, and the migration of comprehensive genomic profiling into routine, reimbursed clinical pathways.
  • The global Next Generation Sequencing market is growing at a CAGR of 13.9% during the forecast period from 2026 to 2034.
  • By offering, the consumables segment dominated the Next Generation Sequencing market with a 51% share in 2025.
  • By technology, the sequencing by synthesis segment dominated the Next Generation Sequencing market with a share of 62% in 2025.
  • By application, the oncology segment dominated the Next Generation Sequencing market with a share of 41% in 2025.
  • By end-user, the academic and research institutes segment dominated the Next Generation Sequencing market with a share of 36% in 2025.
  • North America dominated the global Next Generation Sequencing market revenue with a share of 42% in 2025, representing the highest regional market share globally.

Next Generation Sequencing (NGS), also known as high-throughput or massively parallel sequencing, refers to a family of technologies that read millions of DNA or RNA fragments in parallel, producing whole-genome, whole-exome, or targeted sequence data in hours rather than years. The category spans short-read platforms based on sequencing by synthesis and semiconductor sequencing, alongside long-read single-molecule and nanopore systems, all supported by a workflow of library preparation consumables, instruments, bioinformatics software, and outsourced sequencing services. Over the past decade, NGS has moved from a research instrument into a clinical infrastructure used across oncology, reproductive health, rare disease diagnosis, infectious disease surveillance, and pharmacogenomics.

Next Generation Sequencing Market Key Growth Drivers

  • The cost of sequencing a human genome has declined dramatically, from approximately USD 95 million in 2001 to USD 525 million in 2022, and further to around USD 200 at high-throughput sequencing centers in 2023, significantly improving affordability and accessibility.
  • The increasing global cancer burden is driving demand for NGS-based diagnostics, with 20 million new cancer cases reported in 2022 and projections indicating 35 million cases by 2050.
  • Growing adoption of NGS for tumor profiling, precision oncology, and companion diagnostics is supporting market growth.
  • Expanding clinical applications in reproductive health screening, rare disease diagnosis, and infectious disease surveillance are increasing the utilization of NGS technologies.
  • Technological advancements, including the development of long-read sequencing platforms and AI-enabled bioinformatics solutions, are enhancing sequencing accuracy, efficiency, and data interpretation.
  • Continued government and public-sector investments in genomics research through national genome initiatives and precision medicine programs are accelerating market adoption.
  • The convergence of declining sequencing costs, expanding clinical applications, technological innovation, and supportive funding is expected to sustain strong double-digit growth in the global NGS market through 2034.

Key Companies in Next Generation Sequencing Market

The competitive landscape is led by the following active manufacturers and service providers:

1. Illumina, Inc.

2. Thermo Fisher Scientific Inc.

3. F. Hoffmann-La Roche Ltd

4. QIAGEN N.V.

5. Pacific Biosciences of California, Inc.

6. Oxford Nanopore Technologies plc

7. BGI Genomics Co., Ltd.

8. Agilent Technologies, Inc.

9. Bio-Rad Laboratories, Inc.

10. Revvity, Inc.

Factors Contributing to the Growth of the Next-Generation Sequencing Market

Market Drivers

Rapid Decline in Sequencing Costs Driving Widespread Adoption

The cost of sequencing a human genome has fallen dramatically from approximately USD 95 million in 2001 to USD 525 million in 2022, with leading high-throughput centers achieving the USD 200 genome in 2023. This significant reduction has transformed NGS from a research-focused technology into a cost-effective clinical and population health tool, enabling broader adoption across oncology, rare disease diagnostics, reproductive health, and large-scale screening programs.

Increasing Global Cancer Burden Accelerating Demand for Genomic Profiling

The growing incidence of cancer continues to be a major catalyst for NGS adoption. According to the International Agency for Research on Cancer (IARC), approximately 20 million new cancer cases were diagnosed in 2022, with cases projected to reach 35 million by 2050. As precision oncology and targeted therapies become standard of care, comprehensive genomic profiling and companion diagnostics are increasingly required for treatment selection, driving demand for NGS-based testing and related consumables.

Market Restraints

Despite strong momentum, the Next Generation Sequencing market faces material constraints. Regulatory complexity remains significant, as NGS-based in vitro diagnostics must navigate evolving FDA, European IVDR, and national clinical-laboratory frameworks, lengthening time to market for new assays. High capital costs for instruments and the dominance of consumables expenditure keep the true per-genome cost above headline figures, limiting adoption among smaller laboratories. Manufacturing and supply-chain limitations, including reliance on a concentrated set of reagent and flow-cell suppliers, expose laboratories to availability risk. Reimbursement remains uneven across geographies and indications, with coverage well established for oncology and prenatal testing but inconsistent for broader applications. Finally, a shortage of skilled bioinformaticians and the burden of data storage, interpretation, and clinical reporting, sometimes described as the USD 100,000 analysis behind the USD 1,000 genome, constrain throughput and slow adoption in resource-limited settings.

Next Generation Sequencing Market Segment Analysis

The Next Generation Sequencing Market by Offering (Consumables, Instruments and Platforms, Services), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Others), Application (Oncology, Reproductive Health, Clinical Investigation and Diagnostics, Drug Discovery and Personalized Medicine, Agrigenomics and Forensics, Consumer Genomics, Others), End-Users (Academic and Research Institutes, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Offering

Dominant Subsegment: Consumables. The consumables category is expected to dominate the market.

The consumables segment accounted for 51% of the Next Generation Sequencing market in 2025. Consumables, comprising library preparation kits, reagents, flow cells, barcodes, and target enrichment panels, are consumed on every sequencing run, producing recurring revenue that scales directly with testing volume. The structural decline in sequencing cost has expanded run volumes across oncology, reproductive health, and infectious disease testing, deepening consumables demand. Manufacturers reinforce this dynamic through bundled contracts that pair instruments with proprietary reagents, locking laboratories into recurring purchases. Recent launches illustrate continued innovation in this tier: QIAGEN introduced its QIAseq xHYB Long Read Panels in July 2025 to extend target enrichment to long-read platforms, and Illumina launched Illumina Protein Prep in September 2025 to bring proteomics into the sequencing consumables portfolio. The combination of recurring economics, expanding clinical volumes, and a steady cadence of new kit chemistries supports the segment's continued leadership across the forecast period, while the instruments and platforms tier underpins the installed base, and the services tier captures outsourced demand from laboratories that prefer not to run sequencing in-house.

By Technology

Dominant Subsegment: Sequencing by Synthesis. The sequencing by synthesis category is expected to dominate the market.

The sequencing by synthesis segment accounted for 62% of the Next Generation Sequencing market in 2025. Sequencing by synthesis is the most widely deployed NGS chemistry, valued for its high accuracy, scalability, and the lowest cost per gigabase among current platforms, which has made it the default choice for high-throughput clinical and research laboratories. Its dominance is reinforced by the breadth of validated assays, established bioinformatics pipelines, and a large global installed base of short-read instruments. Continued platform innovation sustains the segment, including ongoing throughput and cost improvements across high-capacity systems and the pursuit of the sub-USD 200 genome. Adjacent technologies are advancing rapidly: long-read single-molecule real-time and nanopore platforms are gaining share in structural variant detection and de novo assembly, and Roche introduced its sequencing-by-expansion chemistry in February 2025 as a new high-throughput approach. While these alternatives expand the technology landscape and grow quickly from smaller bases, sequencing by synthesis retains leadership through its accuracy, cost efficiency, and entrenched clinical validation across the forecast period.

By End-User

Dominant Subsegment: Academic and Research Institutes. The academic and research institutes category is expected to dominate the market.

The academic and research institutes segment accounted for 36% of the Next Generation Sequencing market in 2025. Academic and research institutes remain the largest end user because they conduct the foundational genomics, oncology, and population-scale studies that consume large volumes of sequencing capacity and consumables. National genomics programs and university medical centers operate high-throughput core facilities and sustain demand through grant-funded research, supported by ongoing public investment from agencies such as the National Institutes of Health and the National Human Genome Research Institute. These institutions are early adopters of new platforms and chemistries, driving instrument placements and consumables uptake. At the same time, the migration of NGS into routine care is enlarging the hospitals and clinics and clinical and diagnostic laboratories segments, which are growing quickly as comprehensive genomic profiling, prenatal screening, and infectious disease testing move into reimbursed clinical pathways. Pharmaceutical and biotechnology companies also contribute substantial demand through biomarker discovery and companion diagnostic development. While the clinical end users are the fastest-expanding cohort over the forecast period, academic and research institutes retain leadership in 2025 on the strength of research volume and public funding.

Next Generation Sequencing Market Region Analysis

Dominant Region: North America

North America accounted for 42% of the global Next Generation Sequencing market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the concentration of sequencing manufacturers, academic medical centers, and clinical laboratories in the United States, together with the most developed reimbursement environment for genomic testing. Market-size influence is amplified by high per-capita testing volumes in oncology and reproductive health and by early adoption of long-read sequencing. Healthcare infrastructure is mature, with comprehensive cancer centers and accredited molecular laboratories supporting routine genomic profiling. The regulatory environment is supportive: the FDA provides established pathways for NGS-based in vitro diagnostics, and the Centers for Medicare and Medicaid Services granted reimbursement of USD 2,989.55 per test for TruSight Oncology Comprehensive, effective January 2026. Disease burden is substantial, with about 2 million new cancer cases diagnosed annually in the United States, and the investment landscape is strong, sustained by National Institutes of Health and National Human Genome Research Institute funding alongside private capital concentrated in California and the Northeast.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Next Generation Sequencing market. The region's elevated CAGR is driven by rising healthcare investment, expanding genomic research capacity, and growing clinical adoption across China, Japan, India, South Korea, and Australia. Government initiatives, including national genomics and precision-medicine programs, are funding sequencing infrastructure and population-scale projects. Manufacturing expansion is notable, with domestic platform developers scaling production and lowering local costs. Emerging opportunities span agricultural genomics, infectious disease surveillance, and direct-to-consumer testing, supported by a large patient population and increasing collaborations between local and international companies, such as the April 2025 partnership between Gene Solutions and Element Biosciences to deliver cost-effective prenatal and oncology assays across Southeast Asia.

Regional Commentary

North America

North America accounted for 42% of the global Next Generation Sequencing market revenue in 2025. The United States dominates the region on the strength of its manufacturing base, clinical laboratory network, and reimbursement leadership, while Canada contributes through provincial genomics programs and Mexico advances population genomics initiatives such as large-scale national sequencing projects.

Europe

Europe represents the second-largest regional market, led by Germany, the United Kingdom, and France. Growth is supported by national genomics initiatives, public research funding, and the transition to the European In Vitro Diagnostic Regulation, which is raising the bar for clinical NGS assays. Oxford Nanopore's GridION Dx received CE and UKCA markings in early 2026, marking the first IVD-registered nanopore device for the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by healthcare investment, expanding research activity, and government precision-medicine programs across China, Japan, India, South Korea, and Australia. Domestic manufacturers are scaling capacity and broadening access to cost-effective sequencing, while agricultural genomics and infectious disease applications add demand beyond clinical diagnostics.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Rising healthcare investment, improving laboratory infrastructure, and international collaborations are expanding access. Illumina renewed its partnership with the Africa Centres for Disease Control and Prevention in March 2025 to equip national laboratories with sequencing tools, strengthening genomic surveillance capacity across the continent.

Next Generation Sequencing Market Competitive Landscape

The Next Generation Sequencing market is classified as Consolidated. A small group of global platform providers controls the majority of instrument and consumables revenue, with Illumina holding the leading position in short-read sequencing platforms, followed by Thermo Fisher Scientific in semiconductor sequencing and a long-read duopoly formed by Oxford Nanopore Technologies and Pacific Biosciences. A broader field of reagents, panels, bioinformatics, and service providers competes in the surrounding value chain.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Consolidated, with platform revenue concentrated among a few leaders and high barriers to entry from proprietary chemistry and installed-base lock-in.
  • Leading players: Illumina, Thermo Fisher Scientific, Roche, QIAGEN, Pacific Biosciences, and Oxford Nanopore Technologies anchor the top tier.
  • Geographic reach: Leaders operate global commercial and support networks, with expansion programs targeting Africa, Southeast Asia, and Latin America.
  • Product portfolio strength: Top players offer integrated portfolios spanning instruments, consumables, library preparation, and bioinformatics.
  • Pipeline strength: Active pipelines in long-read accuracy, higher throughput, new chemistries such as sequencing by expansion, and clinical IVD assays.
  • Strategic partnerships: Collaborations with diagnostics firms, cloud and GPU providers, and public health agencies extend reach and capability.
  • M&A activity: Consolidation continues across companion diagnostics, bioinformatics, and liquid biopsy assets.
  • Manufacturing capabilities: Scale manufacturing of flow cells and reagents is a key competitive moat and a supply-chain risk.
  • Innovation focus: Cost reduction toward the sub-USD 200 genome, long-read clinical validation, and AI-assisted interpretation.

Next Generation Sequencing Market Recent Developmental Activities

In January 2026, Illumina, Inc. (with the Centers for Medicare and Medicaid Services), CMS granted national reimbursement for the FDA-approved TruSight Oncology Comprehensive genomic profiling test at USD 2,989.55 per test, effective January 1, 2026. Strategic significance: Establishes durable payer support for large-panel comprehensive genomic profiling, pulling NGS oncology testing into routine reimbursed clinical practice.

In January 2026, Oxford Nanopore Technologies plc Announced that GridION Dx received CE and UKCA markings, the vendor's first in vitro diagnostic device registered in the United Kingdom and Europe, with an initial application in infectious disease characterization through a collaboration with bioMerieux to run the AmPore-TB assay for multidrug-resistant tuberculosis. Strategic significance: Positions nanopore sequencing for regulated clinical diagnostics and validates long-read platforms for infectious disease testing.

In January 2026, Pacific Biosciences of California, Inc., announced plans to collaborate with the nonprofit organizations n-Lorem Foundation and EspeRare to support development of individualized antisense oligonucleotide therapies for ultra-rare genetic disorders. Strategic significance: Extends long-read sequencing into individualized rare-disease therapeutic development, opening a differentiated clinical-research channel.

In January 2026, Daisy Genomics, Inc. (formerly Armonica Technologies) secured USD 2.5 million in seed funding led by Cottonwood Technology Fund and Tramway Venture Partners to advance a spectroscopy-based DNA and RNA sequencing platform toward commercialization. Strategic significance: Signals continued investor appetite for alternative sequencing chemistries that could broaden platform competition.

Next Generation Sequencing Market Segmentation

Next Generation Sequencing Market by Offering

  • Consumables
  • Instruments and Platforms
  • Services

Next Generation Sequencing Market by Technology

  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Single-Molecule Real-Time (SMRT) Sequencing
  • Nanopore Sequencing
  • Others

Next Generation Sequencing Market by Application

  • Oncology
  • Reproductive Health
  • Clinical Investigation and Diagnostics
  • Drug Discovery and Personalized Medicine
  • Agrigenomics and Forensics
  • Consumer Genomics
  • Others

Next Generation Sequencing Market by End-Users

  • Academic and Research Institutes
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Clinical and Diagnostic Laboratories
  • Others

Next Generation Sequencing Market by Geography

  • North America Next Generation Sequencing Market
  • United States Next Generation Sequencing Market Size in USD million (2023-2034)
  • Canada Next Generation Sequencing Market Size in USD million (2023-2034)
  • Mexico Next Generation Sequencing Market Size in USD million (2023-2034)
  • Europe Next Generation Sequencing Market
  • Germany Next Generation Sequencing Market Size in USD million (2023-2034)
  • United Kingdom Next Generation Sequencing Market Size in USD million (2023-2034)
  • France Next Generation Sequencing Market Size in USD million (2023-2034)
  • Italy Next Generation Sequencing Market Size in USD million (2023-2034)
  • Spain Next Generation Sequencing Market Size in USD million (2023-2034)
  • Rest of Europe Next Generation Sequencing Market Size in USD million (2023-2034)
  • Asia-Pacific Next Generation Sequencing Market
  • China Next Generation Sequencing Market Size in USD million (2023-2034)
  • Japan Next Generation Sequencing Market Size in USD million (2023-2034)
  • India Next Generation Sequencing Market Size in USD million (2023-2034)
  • Australia Next Generation Sequencing Market Size in USD million (2023-2034)
  • South Korea Next Generation Sequencing Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Next Generation Sequencing Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Next Generation Sequencing Market
  • Middle East Next Generation Sequencing Market Size in USD million (2023-2034)
  • Africa Next Generation Sequencing Market Size in USD million (2023-2034)
  • South America Next Generation Sequencing Market Size in USD million (2023-2034)

Key Takeaways from the Next Generation Sequencing Market Report Study

  • Market size analysis for the current next generation sequencing market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global next generation sequencing market.
  • Various opportunities available for competitors in the next generation sequencing market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current next generation sequencing market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for next generation sequencing market growth in the future?

Target audience who can benefit from this next generation sequencing market report study

  • Next Generation Sequencing product providers
  • Research organizations and consulting companies
  • Next Generation Sequencing-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in next generation sequencing
  • Various end-users who want to know more about the next generation sequencing market and the latest technological developments in the next generation sequencing market.

Frequently Asked Questions:

Q1. What is the growth rate of the Next Generation Sequencing market?

The Next Generation Sequencing market is projected to expand at a CAGR of 13.9% during the forecast period of 2026-2034.

Q2. What is the market size of the Next Generation Sequencing market?

The Next Generation Sequencing market is estimated at USD 13.24 billion in 2025 and is projected to reach USD 42.68 billion by 2034.

Q3. Which region dominates the Next Generation Sequencing market?

North America dominated the Next Generation Sequencing market with a 42% share of global revenue in 2025, supported by a dense base of sequencing manufacturers and clinical laboratories, FDA pathways for NGS-based diagnostics, strong reimbursement, including CMS coverage of comprehensive genomic profiling, and sustained federal genomics funding. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Next Generation Sequencing market?

The principal drivers are the collapsing cost of sequencing, with the cost per human genome falling from USD 95 million in 2001 to USD 525 by 2022 and to the USD 200 level in 2023 per the National Human Genome Research Institute; the rising global cancer burden, projected by the International Agency for Research on Cancer to increase from 20 million new cases in 2022 to 35 million by 2050; and the maturation of long-read sequencing and AI-assisted bioinformatics, reinforced by expanding clinical reimbursement.

Q5. Who are the major players in the Next Generation Sequencing market?

The major players include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, BGI Genomics Co., Ltd., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., and Revvity, Inc., among other active manufacturers and service providers profiled in the Competitive Landscape section. Illumina leads short-read platforms, while Oxford Nanopore and Pacific Biosciences anchor the long-read segment.

Table of Contents

1. Next Generation Sequencing Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Next Generation Sequencing Market Executive Summary

  • 2.1 Market at a Glance

3. Next Generation Sequencing Market Key Factors Analysis

  • 3.1 Next Generation Sequencing Market Drivers
    • 3.1.1 Structural Decline in Sequencing Cost
    • 3.1.2 Rising Global Cancer and Genetic Disorder Burden
    • 3.1.3 Maturation of Long-Read Sequencing and AI Bioinformatics
    • 3.1.4 Expanding Clinical Reimbursement and Public Genomics Funding
  • 3.2 Next Generation Sequencing Market Restraints and Challenges
    • 3.2.1 Regulatory Complexity and IVDR Transition
    • 3.2.2 High Capital and Consumables Cost
    • 3.2.3 Bioinformatics, Data Storage, and Skilled-Workforce Constraints
  • 3.3 Next Generation Sequencing Market Opportunities
    • 3.3.1 Liquid Biopsy and Minimal Residual Disease Monitoring
    • 3.3.2 Emerging-Market Expansion and Population Genomics

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Next Generation Sequencing Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Next Generation Sequencing Market Assessment

  • 7.1 By Offering
    • 7.1.1 Consumables
    • 7.1.2 Instruments and Platforms
    • 7.1.3 Services
  • 7.2 By Technology
    • 7.2.1 Sequencing by Synthesis
    • 7.2.2 Ion Semiconductor Sequencing
    • 7.2.3 Single-Molecule Real-Time Sequencing
    • 7.2.4 Nanopore Sequencing
    • 7.2.5 Others
  • 7.3 By Application
    • 7.3.1 Oncology
    • 7.3.2 Reproductive Health
    • 7.3.3 Clinical Investigation and Diagnostics
    • 7.3.4 Drug Discovery and Personalized Medicine
    • 7.3.5 Agrigenomics and Forensics
    • 7.3.6 Consumer Genomics
    • 7.3.7 Others
  • 7.4 By End User
    • 7.4.1 Academic and Research Institutes
    • 7.4.2 Hospitals and Clinics
    • 7.4.3 Pharmaceutical and Biotechnology Companies
    • 7.4.4 Clinical and Diagnostic Laboratories
    • 7.4.5 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.1.2 Canada Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.1.3 Mexico Next Generation Sequencing Market Size in USD million (2023-2034)
    • 7.5.2 Europe
      • 7.5.2.1 Germany Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.2.2 United Kingdom Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.2.3 France Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.2.4 Italy Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.2.5 Spain Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.2.6 Rest of Europe Next Generation Sequencing Market Size in USD million (2023-2034)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.3.2 Japan Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.3.3 India Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.3.4 Australia Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.3.5 South Korea Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.3.6 Rest of Asia-Pacific Next Generation Sequencing Market Size in USD million (2023-2034)
    • 7.5.4 Rest of World
      • 7.5.4.1 Middle East Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.4.2 Africa Next Generation Sequencing Market Size in USD million (2023-2034)
      • 7.5.4.3 South America Next Generation Sequencing Market Size in USD million (2023-2034)

8. Next Generation Sequencing Market Competitive Landscape

  • 8.1 Market Concentration and Structure

9. Next Generation Sequencing Market Startup Funding and Investment Trends

10. Next Generation Sequencing Market Company and Product Profiles

  • 10.1 Illumina, Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Thermo Fisher Scientific Inc.
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 F. Hoffmann-La Roche Ltd
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 QIAGEN N.V.
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Pacific Biosciences of California, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 Oxford Nanopore Technologies plc
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 BGI Genomics Co., Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Agilent Technologies, Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Bio-Rad Laboratories, Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10.10 Revvity, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Next Generation Sequencing Market in Global (2023-2034)
  • Table 2: Next Generation Sequencing Market in Global by Offering (2023-2034)
  • Table 3: Next Generation Sequencing Market in Global by Technology (2023-2034)
  • Table 4: Next Generation Sequencing Market in Global by Application (2023-2034)
  • Table 5: Next Generation Sequencing Market in Global by End-Users (2023-2034)
  • Table 6: Next Generation Sequencing Market in Global by Geography (2023-2034)
  • Table 7: Next Generation Sequencing Market in North America (2023-2034)
  • Table 8: Next Generation Sequencing Market in the United States (2023-2034)
  • Table 9: Next Generation Sequencing Market in Canada (2023-2034)
  • Table 10: Next Generation Sequencing Market in Mexico (2023-2034)
  • Table 11: Next Generation Sequencing Market in Europe (2023-2034)
  • Table 12: Next Generation Sequencing Market in France (2023-2034)
  • Table 13: Next Generation Sequencing Market in Germany (2023-2034)
  • Table 14: Next Generation Sequencing Market in United Kingdom (2023-2034)
  • Table 15: Next Generation Sequencing Market in Italy (2023-2034)
  • Table 16: Next Generation Sequencing Market in Spain (2023-2034)
  • Table 17: Next Generation Sequencing Market in the Rest of Europe (2023-2034)
  • Table 18: Next Generation Sequencing Market in Asia-Pacific (2023-2034)
  • Table 19: Next Generation Sequencing Market in China (2023-2034)
  • Table 20: Next Generation Sequencing Market in Japan (2023-2034)
  • Table 21: Next Generation Sequencing Market in India (2023-2034)
  • Table 22: Next Generation Sequencing Market in Australia (2023-2034)
  • Table 23: Next Generation Sequencing Market in South Korea (2023-2034)
  • Table 24: Next Generation Sequencing Market in Rest of Asia-Pacific (2023-2034)
  • Table 25: Next Generation Sequencing Market in the Rest of the World (2023-2034)
  • Table 26: Next Generation Sequencing Market in the Middle East (2023-2034)
  • Table 27: Next Generation Sequencing Market in Africa (2023-2034)
  • Table 28: Next Generation Sequencing Market in South America (2023-2034)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Next Generation Sequencing Market Drivers
  • Figure 2: Next Generation Sequencing Market Restraints
  • Figure 3: Next Generation Sequencing Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Next Generation Sequencing Market in Global (2023-2034)
  • Figure 9: Next Generation Sequencing Market in Global by Offering (2023-2034)
  • Figure 10: Next Generation Sequencing Market in Global by Technology (2023-2034)
  • Figure 11: Next Generation Sequencing Market in Global by Application (2023-2034)
  • Figure 12: Next Generation Sequencing Market in Global by End-Users (2023-2034)
  • Figure 13: Next Generation Sequencing Market in Global by Geography (2023-2034)
  • Figure 14: Next Generation Sequencing Market in North America (2023-2034)
  • Figure 15: Next Generation Sequencing Market in the United States (2023-2034)
  • Figure 16: Next Generation Sequencing Market in Canada (2023-2034)
  • Figure 17: Next Generation Sequencing Market in Mexico (2023-2034)
  • Figure 18: Next Generation Sequencing Market in Europe (2023-2034)
  • Figure 19: Next Generation Sequencing Market in France (2023-2034)
  • Figure 20: Next Generation Sequencing Market in Germany (2023-2034)
  • Figure 21: Next Generation Sequencing Market in United Kingdom (2023-2034)
  • Figure 22: Next Generation Sequencing Market in Italy (2023-2034)
  • Figure 23: Next Generation Sequencing Market in Spain (2023-2034)
  • Figure 24: Next Generation Sequencing Market in the Rest of Europe (2023-2034)
  • Figure 25: Next Generation Sequencing Market in Asia-Pacific (2023-2034)
  • Figure 26: Next Generation Sequencing Market in China (2023-2034)
  • Figure 27: Next Generation Sequencing Market in Japan (2023-2034)
  • Figure 28: Next Generation Sequencing Market in India (2023-2034)
  • Figure 29: Next Generation Sequencing Market in Australia (2023-2034)
  • Figure 30: Next Generation Sequencing Market in South Korea (2023-2034)
  • Figure 31: Next Generation Sequencing Market in Rest of Asia-Pacific (2023-2034)
  • Figure 32: Next Generation Sequencing Market in the Rest of the World (2023-2034)
  • Figure 33: Next Generation Sequencing Market in the Middle East (2023-2034)
  • Figure 34: Next Generation Sequencing Market in Africa (2023-2034)
  • Figure 35: Next Generation Sequencing Market in South America (2023-2034)
  • Figure 36: Competitive Landscape
  • Figure 37: Startup Funding and Investment Trends